Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity
Journal of Comparative Effectiveness Research · 2023-03 · 12 (3)
DOI: 10.2217/cer-2022-0159 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Journal of Comparative Effectiveness Research, 2023-03. Verfasst von Bart Heeg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cytel RWAA, Weena 316, 3012 NJ, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
This research evaluated standard Weibull mixture cure (WMC) network meta-analysis (NMA) with Bayesian hierarchical (BH) WMC NMA to inform long-term survival of therapies. Materials & methods: Four trials in previously treated metastatic non-small-cell lung cancer with PD-L1 >1% were used comparing docetaxel with nivolumab, pembrolizumab and atezolizumab. Cure parameters related to a certain treatment class were assumed to share a common distribution.
Results
Standard WMC NMA predicted cure rates were 0.03 (0.01; 0.07), 0.18 (0.12; 0.24), 0.07 (0.02; 0.15) and 0.03 (0.00; 0.09) for docetaxel, nivolumab, pembrolizumab and atezolizumab, respectively, with corresponding incremental life years (LY) of 3.11 (1.65; 4.66), 1.06 (0.41; 2.37) and 0.42 (-0.57; 1.68). The Bayesian hierarchical-WMC-NMA rates were 0.06 (0.03; 0.10), 0.17 (0.11; 0.23), 0.12 (0.05; 0.20) and 0.12 (0.03; 0.23), respectively, with incremental LY of 2.35 (1.04; 3.93), 1.67 (0.68; 2.96) and 1.36 (-0.05; 3.64).
Conclusion
BH-WMC-NMA impacts incremental mean LYs and cost–effectiveness ratios, potentially affecting reimbursement decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cytel RWAA, Weena 316, 3012 NJ, Rotterdam, The Netherlands.
- Cytel RWAA, Canada.
- Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.
- Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA.
ORCID-Profile: Bart Heeg, Haitao Chu, Satrajit Roychoudhury, Joseph C Cappelleri
Zitieren
APA
Heeg, B., Verhoek, A., Tremblay, G., Harari, O., Soltanifar, M., Chu, H., Roychoudhury, S., & Cappelleri, J. C. (2023). Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research, 12(3). https://doi.org/10.2217/cer-2022-0159
Vancouver
Heeg B, Verhoek A, Tremblay G, Harari O, Soltanifar M, Chu H, et al. Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity. Journal of Comparative Effectiveness Research. 2023;12(3). doi:10.2217/cer-2022-0159
BibTeX
@article{Heeg2023,
author = {Heeg, Bart and Verhoek, Andre and Tremblay, Gabriel and Harari, Ofir and Soltanifar, Mohsen and Chu, Haitao and Roychoudhury, Satrajit and Cappelleri, Joseph C},
title = {Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity},
journal = {Journal of Comparative Effectiveness Research},
year = {2023},
volume = {12},
number = {3},
doi = {10.2217/cer-2022-0159}
}
EUVIMED